Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2012 08:53 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at ROTH 24th Annual Growth Conference

NEW YORK, March 7, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
February 29, 2012 16:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at 32nd Annual Cowen and Company Health Care Conference

NEW YORK, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), (Nasdaq:SGYPU), (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases,...
December 13, 2011 09:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie

NEW YORK--Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York...
December 13, 2011 04:41 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.

NEW YORK--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the full exercise of the over-allotment option...
December 01, 2011 08:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of 1,875,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split

NEW YORK--Synergy Pharmaceuticals, Inc. (NASDAQ: SGYPD), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the pricing of an underwritten public offering of...
November 15, 2011 05:30 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Raises $5.64 Million in Financing

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has completed a financing in which it...
October 31, 2011 06:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals and Fox Chase Cancer Center Presentation at 2011 ACG Meeting Highlights Potential of GC-C Agonists to Delay Progression of Colitis into Colon Cancer

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011...
October 27, 2011 10:41 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Presentations at 2011 American College of Gastroenterology Annual Scientific Meeting

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the presentation of three posters on plecanatide...
October 24, 2011 06:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Initiates Dosing of Patients in Phase II/III Trial of Plecanatide in Chronic Constipation

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced initiation of dosing of patients in a major...
June 03, 2011 04:21 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Gary S. Jacob, President and Chief...